
Why Moderna’s Bold Bet on mRNA Could Be Your Next Big Investment
Moderna is transitioning from pandemic-specific success to broader biotech ventures despite financial turbulence. Spikevax maintains strong market presence, garnering significant revenue and highlighting continued COVID-19 vaccine demand. The company’s diverse pipeline includes approved RSV vaccine mRESVIA and promising COVID/flu and other infectious